Role of Antibodies Against Glutamate Receptors and Double Stranded DNA in Epilepsy Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00317668
Recruitment Status : Unknown
Verified April 2006 by Hadassah Medical Organization.
Recruitment status was:  Recruiting
First Posted : April 25, 2006
Last Update Posted : May 1, 2007
Information provided by:
Hadassah Medical Organization

Brief Summary:
The investigators will check the serum of epilepsy patients for antibodies against glutamate receptors and double stranded DNA. They will characterise the patients (by the kind of epilepsy, autoimmune disease comorbidity, and cognitive profile).

Condition or disease

Study Type : Observational
Estimated Enrollment : 250 participants
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Retrospective/Prospective
Study Start Date : November 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 120 epilepsy patients from the epilepsy clinic and Emergency Room (ER)
  • Controls: 100 patients with other neurological diseases and no epilepsy; and 30 healthy volunteers.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00317668

Contact: Dana Ekstein, MD

Hadassah Ein-Kerem Medical Center Recruiting
Jerusalem, Israel
Principal Investigator: Dana Ekstein, MD         
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Dana Ekstein, MD Hadassah Medical Organization Identifier: NCT00317668     History of Changes
Other Study ID Numbers: autoimmunepi-HMO-CTIL
First Posted: April 25, 2006    Key Record Dates
Last Update Posted: May 1, 2007
Last Verified: April 2006

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases